Redefining extended-spectrum beta-lactamases: Balancing science and clinical need

Giske, Christine G., Sundsfjord, Arnfinn S., Kahlmeter, Gunnar, Woodford, Neil, Nordmann, Patrice, Paterson, David L., Canton, Rafael and Walsh, Timothy R. (2009) Redefining extended-spectrum beta-lactamases: Balancing science and clinical need. Journal of Antimicrobial Chemotherapy, 63 1: 1-4. doi:10.1093/jac/dkn444

Author Giske, Christine G.
Sundsfjord, Arnfinn S.
Kahlmeter, Gunnar
Woodford, Neil
Nordmann, Patrice
Paterson, David L.
Canton, Rafael
Walsh, Timothy R.
Title Redefining extended-spectrum beta-lactamases: Balancing science and clinical need
Formatted title
Redefining extended-spectrum ß-lactamases: Balancing science and clinical need
Journal name Journal of Antimicrobial Chemotherapy   Check publisher's open access policy
ISSN 0305-7453
Publication date 2009-01
Year available 2009
Sub-type Article (original research)
DOI 10.1093/jac/dkn444
Volume 63
Issue 1
Start page 1
End page 4
Total pages 4
Editor A.P. Johnson
Place of publication Oxford, United Kingdom
Publisher Oxford University Press
Collection year 2010
Language eng
Subject C1
920109 Infectious Diseases
110309 Infectious Diseases
Abstract The current beta-lactamase classifications have reached a high level of complexity, making them less accessible to clinicians, infection control professionals, hospital management and politicians. From the clinical perspective, a revised comprehensible nomenclature scheme is therefore needed. The term extended-spectrum beta-lactamases (ESBLs) has reached a broader audience over time, but is currently restricted to functional class 2be/molecular class A, clavulanic acid inhibited enzymes with activity against extended-spectrum cephalosporins. The proposed new classification expands the definition of ESBL to other clinically important acquired beta-lactamases with activity against extended-spectrum cephalosporins and/or carbapenems. The classical class A ESBLs have been designated ESBLA in this classification, whereas plasmid-mediated AmpC and OXA-ESBLs are classed as miscellaneous ESBLs (ESBLM). Lastly, the carbapenemases have been designated ESBLCARBA, ESBLs with hydrolytic activity against carbapenems. We believe that this simplified classification may encourage new groups of healthcare professionals to engage in the effort to prevent the spread of acquired beta-lactamases
Keyword Classification
Q-Index Code C1
Q-Index Status Confirmed Code

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
2010 Higher Education Research Data Collection
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 48 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 61 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 03 Sep 2009, 09:10:06 EST by Mr Andrew Martlew on behalf of UQ Centre for Clinical Research